LY2886721

Overview

LY2886721 is a potent, selective and orally active beta-site amyloid precursor protein cleaving enzyme 1 ( BACE1 ) inhibitor with an IC 50 of 20.3 nM for recombinant human BACE1 . LY2886721 is selectivity against cathepsin D , pepsin, and renin , but lacking selectivity against BACE2 ( IC 50 of 10.2 nM). LY2886721 can across blood-brain barrier and has the potential for Alzheimer's disease treatment.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Alzheimer's Disease | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Beta-secretase

Product Information

• Catalog No.: HY-13240
• CAS No.: 1262036-50-9
• Molecular Formula: C18H16F2N4O2S
• Molecular Weight: 390.41
• Purity: 99.72%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2 mg/mL (5.12 mM); Clear solution
• Availability: In-stock

Source

Original product source